Thrombosis Risk Assessment & Clinical Presentation of Covid-19 Pneumonia

Status Completed

Clinical Trial Summary

Covid-19 mainly affects the respiratory system. Multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. In this study, the association between thrombosis risk and clinical presentation of Covid-19 is investigated.

Clinical Trial Description

The severe acute respiratory distress syndrome related coronavirus-2 (SARS-CoV-2) and its clinical presentation as Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, Hubei, China in December 2019. It has spread rapidly from its origin in Wuhan City to other countries of the world over the last several months.

Although it mainly affects the respiratory system , multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. SARS-CoV-2 infection may also lead to thrombotic disease both in the venous and arterial circulation of patients apart from respiratory system due to excessive inflammation, thrombocyte activation, endothelial malfunction, and stasis.

Investigators have reported that both CHADS2 and CHA2DS2-VASc scores were related to mortality in individuals that had stable coronary angina, acute coronary syndrome, Takotsubo syndrome or sick sinus syndrome, apart from atrial fibrillation . In addition, thrombocyte/lymphocyte (PLT/LYM) and neutrophil/lymphocyte (NEU/LYM) ratios on admission were also related with thromboembolic complications in former studies which found them useful to predict prognosis of acute pulmonary embolism, as being one of the thromboembolic complications of Covid-19.

Investigators suggest that the parameters mentioned above should also be studied in terms of thrombotic complications of Covid-19. Thus they aimed to find out potential associations between markers of prothrombotic or inflammatory conditions and some clinical features of Covid-19 pneumonia cases on admission and follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04423315
Study type	Observational
Source	Nisantasi University
Contact
Status	Completed
Phase
Start date	June 8, 2020
Completion date	July 20, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04384445` - Zofin (Organicell Flow) for Patients With COVID-19	Phase 1/Phase 2
Completed	`NCT04578210` - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia	Phase 1/Phase 2
Completed	`NCT05065827` - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed	`NCT04720794` - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion	N/A
Enrolling by invitation	`NCT04659486` - Adolescents With COVID-19/MIS-C at HCFMUSP	N/A
Completed	`NCT04598620` - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed	`NCT05517941` - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient	N/A
Recruiting	`NCT04480333` - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831	Phase 1
Recruiting	`NCT04565782` - Corona Virus Infection Among Liver Transplant Recipients
Active, not recruiting	`NCT04558476` - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation	Phase 2
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Completed	`NCT05639998` - BBV152/BBV154 Heterologus Prime-Boost Study	Phase 2
Withdrawn	`NCT04386447` - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	Phase 2
Completed	`NCT05736926` - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Completed	`NCT04523246` - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents	Early Phase 1
Recruiting	`NCT04583566` - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed	`NCT04643678` - Anakinra in the Management of COVID-19 Infection	Phase 2/Phase 3
Recruiting	`NCT04579588` - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated	`NCT03331445` - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections	Phase 2
Recruiting	`NCT04573348` - T Cells Response to SARS COV 2 Peptides

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia — Covid-19

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms